OSL : Follow-up

Since my last post on OSL (ASX : OSL), I’ve had a few interesting reach-outs confirming my viewpoint on this company and also providing a bit more “colour”. I should note that all of this information is actually reasonably consistent with the discussion I had with Daniel Kenny (CEO) last week, with one exception and I…

Wazzup ResApp?

This post represents the first in a series of THREE posts that I have written at the request of readers. After my slightly sarcastic review of iSonea where I sort of lumped iSonea and ResApp together in to the “turd” category, but without any real elaboration, I had several requests for clarification. Incidentally, I appreciate it…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…

The Bioshares 2015 : “Long Tail” Awards

Unfortunately, I will not be at Bioshares in New Zealand this weekend to present these well-deserved awards on behalf of the dedicated readers of The Long Tail. However, I have ordered a crate of North Korean Kumdang-2 as the prize for these awards and as soon as it clears AQIS, I will be sure and distribute…

PAA: Congratulations to Roger and the team…

Monumental day! Well done, another bit of doggy data for PharmAust … to follow all the other bits of doggy data we have received this year. Yaaaay! I think for all the world’s cancer patients, Executive Chairman Dr. Roger Aston’s comments bode particularly well, especially for women : Combining chemotherapy with PPL-1 in a target species with…

Immuron’s Revolving Door

Immuron (ASX : IMC) is one of those Long Tail companies that has become such an entrenched part of the fantasy and delusion of ASX biotech that it would be hardly worth a mention, were it not for recent events. At some stage I will write a longer piece as to why IMC’s technology is…

The Next Great ASX Biotech?

Every once in a while I read a news item that leaves me in a state of semi-shock and, let’s face it, that is a pretty high bar given the messed-up world we live in. This weekend, I spent a bit of time catching up on current affairs (as one does on a lazy Sunday morning) and…